Beacon Therapeutics reported that its gene therapy for X-linked retinitis pigmentosa (XLRP) succeeded in a pivotal trial, improving visual acuity and positioning the company to pursue regulatory approval. The result adds momentum for Beacon after years in which larger peers have struggled to translate gene therapy approaches into meaningful, durable vision outcomes in this rare inherited disease. Beacon’s announcement frames the trial readout as a key step toward filing with the FDA. For the broader gene-therapy sector, it signals continued progress in ophthalmology, an area where clinical endpoints and durability of effect remain central gating issues. The company also benefits from heightened attention to scalable manufacturing and long-term follow-up expectations for retinal gene treatments—issues regulators and investors increasingly focus on.